Ascension St John Hospital
- Type
- Teaching hospital
- Where
- Detroit, MI
- Medicare CCN
- 230165
- Received
- $1,666,846 in 182 records, 2022 ($31,060 general, $1,635,786 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2022 | General payment | 7 | $31,060 |
| 2022 | Research payment | 175 | $1,635,786 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| PFIZER INC. | 33 | $779,072 | 2022 |
| JAZZ PHARMACEUTICALS INC. | 4 | $385,125 | 2022 |
| Medtronic, Inc. | 32 | $116,184 | 2022 |
| Genetesis, Inc. | 10 | $101,430 | 2022 |
| Genentech, Inc. | 21 | $63,899 | 2022 |
| Saranas, Inc. | 24 | $46,123 | 2022 |
| Eli Lilly and Company | 2 | $34,700 | 2022 |
| Penumbra, Inc. | 18 | $32,965 | 2022 |
| AngioDynamics, Inc. | 2 | $25,333 | 2022 |
| Abbott Laboratories | 11 | $23,225 | 2022 |
| Gilead Sciences, Inc. | 9 | $16,890 | 2022 |
| E.R. Squibb & Sons, L.L.C. | 1 | $14,450 | 2022 |
| Philips North America LLC | 3 | $7,450 | 2022 |
| Endologix LLC | 2 | $4,517 | 2022 |
| Boston Scientific Corporation | 2 | $4,000 | 2022 |
| Alexion Pharmaceuticals, Inc. | 1 | $2,895 | 2022 |
| Genentech USA, Inc. | 1 | $2,000 | 2022 |
| Celgene Corporation | 1 | $1,910 | 2022 |
| Impulse Dynamics (USA) Inc. | 1 | $1,750 | 2022 |
| Wilson Cook Medical Incorporated | 1 | $1,500 | 2022 |
| Octapharma USA, Inc. | 1 | $1,200 | 2022 |
| Cochlear Americas | 1 | $165 | 2022 |
| KARL STORZ Endoscopy-America | 1 | $61 | 2022 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 175 | $1,635,786 |
| Long term medical supply or device loan | 3 | $25,394 |
| Space rental or facility fees (teaching hospital only) | 2 | $3,500 |
| Grant | 1 | $2,000 |
| Debt forgiveness | 1 | $165 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2022-12-31 | AngioDynamics, Inc. | $13,000 | Long term medical supply or device loan | In-kind items and services | Solero Device, Oncology | 2022 | |
| 2022-12-28 | PFIZER INC. | $3,282 | Research payment | Cash or cash equivalent | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI | 2022 | |
| 2022-12-28 | Boston Scientific Corporation | $2,000 | Grant | Cash or cash equivalent | GENERAL - THERAPIES Device, THERAPIES | 2022 | |
| 2022-12-23 | Genentech USA, Inc. | $2,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Activase Biological, Metabolism & Primary Care | 2022 | |
| 2022-12-21 | PFIZER INC. | $4,917 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED | 2022 | |
| 2022-12-21 | PFIZER INC. | $1,072 | Research payment | Cash or cash equivalent | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI | 2022 | |
| 2022-12-19 | Medtronic, Inc. | $3,506 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | CoreValve SURTAVI | 2022 |
| 2022-12-19 | Medtronic, Inc. | $3,506 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | CoreValve SURTAVI | 2022 |
| 2022-12-17 | PFIZER INC. | $10,130 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED | 2022 | |
| 2022-12-16 | PFIZER INC. | $13,488 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED | 2022 | |
| 2022-12-15 | Medtronic, Inc. | $9,179 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | SMART Trial | 2022 |
| 2022-12-15 | Medtronic, Inc. | $9,179 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | SMART Trial | 2022 |
| 2022-12-14 | PFIZER INC. | $5,430 | Research payment | Cash or cash equivalent | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI | 2022 | |
| 2022-12-14 | Genetesis, Inc. | $500 | Research payment | Cash or cash equivalent | MICRO ASJH | 2022 | |
| 2022-12-10 | PFIZER INC. | $32,049 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED | 2022 | |
| 2022-12-07 | Genentech, Inc. | $4,393 | Research payment | Cash or cash equivalent | Xeloda Drug, BioOncology | MYTACTIC TARGETING ACTIONABLE MUTATION STUDY IN CANCER US PIIA MULTICENTER NONRANDOMIZED OPEN LBL | 2022 |
| 2022-12-06 | Wilson Cook Medical Incorporated | $1,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2022 | ||
| 2022-12-03 | PFIZER INC. | $25,768 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED | 2022 | |
| 2022-11-30 | PFIZER INC. | $458 | Research payment | Cash or cash equivalent | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI | 2022 | |
| 2022-11-29 | JAZZ PHARMACEUTICALS INC. | $111,000 | Research payment | Cash or cash equivalent | VYXEOS Drug, HEMATOLOGY/ONCOLOGY | A PHASE 3 RANDOMIZED TRIAL FOR PATIENTS WITH DE NOVO AML COMPARING STANDARD THERAPY INCLUDING GEMTUZUMAB OZOGAMICIN GO T | 2022 |
| 2022-11-28 | Gilead Sciences, Inc. | $993 | Research payment | Cash or cash equivalent | A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhib | 2022 | |
| 2022-11-25 | Abbott Laboratories | $3,000 | Research payment | Cash or cash equivalent | Device, Cardiac Rhythm Management | Safety and Effectiveness Trial for the Nanostim Leadless Pacemaker | 2022 |
| 2022-11-23 | PFIZER INC. | $42,346 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED | 2022 | |
| 2022-11-18 | Penumbra, Inc. | $1,125 | Research payment | Cash or cash equivalent | Indigo System Device, Peripheral Intervention | STRIKE-PE | 2022 |
| 2022-11-16 | PFIZER INC. | $7,698 | Research payment | Cash or cash equivalent | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI | 2022 | |
| 2022-11-14 | Medtronic, Inc. | $500 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | SMART Trial | 2022 |
| 2022-11-14 | Medtronic, Inc. | $500 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | SMART Trial | 2022 |
| 2022-11-10 | PFIZER INC. | $63,157 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED | 2022 | |
| 2022-11-08 | PFIZER INC. | $30,349 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED | 2022 | |
| 2022-11-07 | Saranas, Inc. | $2,208 | Research payment | Cash or cash equivalent | SARANAS SAFE-MCS STUDY | 2022 | |
| 2022-11-07 | Boston Scientific Corporation | $2,000 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | HI PEITHO | 2022 |
| 2022-11-04 | JAZZ PHARMACEUTICALS INC. | $55,500 | Research payment | Cash or cash equivalent | VYXEOS Drug, HEMATOLOGY/ONCOLOGY | A PHASE 3 RANDOMIZED TRIAL FOR PATIENTS WITH DE NOVO AML COMPARING STANDARD THERAPY INCLUDING GEMTUZUMAB OZOGAMICIN GO T | 2022 |
| 2022-11-04 | Genetesis, Inc. | $4,210 | Research payment | Cash or cash equivalent | ACCMED | 2022 | |
| 2022-11-03 | Saranas, Inc. | $1,000 | Research payment | Cash or cash equivalent | SARANAS SAFE-MCS STUDY | 2022 | |
| 2022-11-02 | PFIZER INC. | $2,599 | Research payment | Cash or cash equivalent | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI | 2022 | |
| 2022-10-31 | Genetesis, Inc. | $250 | Research payment | Cash or cash equivalent | MICRO ASJH | 2022 | |
| 2022-10-28 | PFIZER INC. | $15,174 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED | 2022 | |
| 2022-10-27 | PFIZER INC. | $7,395 | Research payment | Cash or cash equivalent | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI | 2022 | |
| 2022-10-26 | Eli Lilly and Company | $17,950 | Research payment | Cash or cash equivalent | A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB (LOXO-305) VERSUS BENDAMUSTINE PLUS RITUXIMAB IN UNTREATED PATIE | 2022 | |
| 2022-10-26 | Abbott Laboratories | $2,630 | Research payment | Cash or cash equivalent | Device, Cardiac Rhythm Management | Safety and Effectiveness Trial for the Nanostim Leadless Pacemaker | 2022 |
| 2022-10-20 | Saranas, Inc. | $2,208 | Research payment | Cash or cash equivalent | SARANAS SAFE-MCS STUDY | 2022 | |
| 2022-10-20 | Saranas, Inc. | $1,173 | Research payment | Cash or cash equivalent | SARANAS SAFE-MCS STUDY | 2022 | |
| 2022-10-18 | PFIZER INC. | $5,058 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED | 2022 | |
| 2022-10-14 | Genetesis, Inc. | $5,000 | Research payment | Cash or cash equivalent | MICRO ASJH | 2022 | |
| 2022-10-13 | Medtronic, Inc. | $1,632 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | TAVR Low Risk | 2022 |
| 2022-10-13 | Medtronic, Inc. | $1,632 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | TAVR Low Risk | 2022 |
| 2022-10-06 | PFIZER INC. | $30,290 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | POLARIS PALBOCICLIB IN HORMONE RECEPTOR POSITIVE ADVANCED BREAST CANCER A PROSPECTIVE MULTICENTER NONINTERVENTIONAL STUD | 2022 |
| 2022-10-06 | Penumbra, Inc. | $2,717 | Research payment | Cash or cash equivalent | Indigo System Device, Peripheral Intervention | STRIKE-PE | 2022 |
| 2022-10-05 | Genentech, Inc. | $155 | Research payment | Cash or cash equivalent | Xeloda Drug, BioOncology | MYTACTIC TARGETING ACTIONABLE MUTATION STUDY IN CANCER US PIIA MULTICENTER NONRANDOMIZED OPEN LBL | 2022 |
| 2022-10-03 | Medtronic, Inc. | $7,104 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | SMART Trial | 2022 |
| 2022-10-03 | Medtronic, Inc. | $7,104 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | SMART Trial | 2022 |
| 2022-09-30 | PFIZER INC. | $19,520 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | POLARIS PALBOCICLIB IN HORMONE RECEPTOR POSITIVE ADVANCED BREAST CANCER A PROSPECTIVE MULTICENTER NONINTERVENTIONAL STUD | 2022 |
| 2022-09-30 | PFIZER INC. | $3,268 | Research payment | Cash or cash equivalent | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI | 2022 | |
| 2022-09-29 | Endologix LLC | $2,567 | Research payment | Cash or cash equivalent | Detour II Study | 2022 | |
| 2022-09-28 | Genentech, Inc. | $2,068 | Research payment | Cash or cash equivalent | Xeloda Drug, BioOncology | MYTACTIC TARGETING ACTIONABLE MUTATION STUDY IN CANCER US PIIA MULTICENTER NONRANDOMIZED OPEN LBL | 2022 |
| 2022-09-26 | Genetesis, Inc. | $8,740 | Research payment | Cash or cash equivalent | ACCMED | 2022 | |
| 2022-09-24 | PFIZER INC. | $26,716 | Research payment | Cash or cash equivalent | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI | 2022 | |
| 2022-09-23 | Saranas, Inc. | $2,208 | Research payment | Cash or cash equivalent | SARANAS SAFE-MCS STUDY | 2022 | |
| 2022-09-23 | Saranas, Inc. | $1,500 | Research payment | Cash or cash equivalent | SARANAS SAFE-MCS STUDY | 2022 | |
| 2022-09-22 | PFIZER INC. | $13,000 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED | 2022 | |
| 2022-09-21 | Gilead Sciences, Inc. | $1,906 | Research payment | Cash or cash equivalent | A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhib | 2022 | |
| 2022-09-15 | Endologix LLC | $1,950 | Research payment | Cash or cash equivalent | Detour II Study | 2022 | |
| 2022-09-14 | Genentech, Inc. | $2,600 | Research payment | Cash or cash equivalent | Xeloda Drug, BioOncology | MYTACTIC TARGETING ACTIONABLE MUTATION STUDY IN CANCER US PIIA MULTICENTER NONRANDOMIZED OPEN LBL | 2022 |
| 2022-09-14 | Genentech, Inc. | $2,040 | Research payment | Cash or cash equivalent | Xeloda Drug, BioOncology | MYTACTIC TARGETING ACTIONABLE MUTATION STUDY IN CANCER US PIIA MULTICENTER NONRANDOMIZED OPEN LBL | 2022 |
| 2022-09-14 | Genentech, Inc. | $2,000 | Research payment | Cash or cash equivalent | Xeloda Drug, BioOncology | MYTACTIC TARGETING ACTIONABLE MUTATION STUDY IN CANCER US PIIA MULTICENTER NONRANDOMIZED OPEN LBL | 2022 |
| 2022-09-14 | Genentech, Inc. | $1,200 | Research payment | Cash or cash equivalent | Xeloda Drug, BioOncology | MYTACTIC TARGETING ACTIONABLE MUTATION STUDY IN CANCER US PIIA MULTICENTER NONRANDOMIZED OPEN LBL | 2022 |
| 2022-09-14 | Genentech, Inc. | $938 | Research payment | Cash or cash equivalent | Xeloda Drug, BioOncology | MYTACTIC TARGETING ACTIONABLE MUTATION STUDY IN CANCER US PIIA MULTICENTER NONRANDOMIZED OPEN LBL | 2022 |
| 2022-09-13 | PFIZER INC. | $7,660 | Research payment | Cash or cash equivalent | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI | 2022 | |
| 2022-09-09 | Medtronic, Inc. | $525 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | Optimize Pro | 2022 |
| 2022-09-09 | Medtronic, Inc. | $525 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | Optimize Pro | 2022 |
| 2022-09-01 | Penumbra, Inc. | $4,995 | Research payment | Cash or cash equivalent | Indigo System Device, Peripheral Intervention | STRIKE-PE | 2022 |
| 2022-08-31 | Saranas, Inc. | $1,173 | Research payment | Cash or cash equivalent | SARANAS SAFE-MCS STUDY | 2022 | |
| 2022-08-31 | Saranas, Inc. | $1,173 | Research payment | Cash or cash equivalent | SARANAS SAFE-MCS STUDY | 2022 | |
| 2022-08-31 | Saranas, Inc. | $1,173 | Research payment | Cash or cash equivalent | SARANAS SAFE-MCS STUDY | 2022 | |
| 2022-08-31 | Saranas, Inc. | $1,035 | Research payment | Cash or cash equivalent | SARANAS SAFE-MCS STUDY | 2022 | |
| 2022-08-31 | Saranas, Inc. | $1,035 | Research payment | Cash or cash equivalent | SARANAS SAFE-MCS STUDY | 2022 | |
| 2022-08-31 | Saranas, Inc. | $1,035 | Research payment | Cash or cash equivalent | SARANAS SAFE-MCS STUDY | 2022 | |
| 2022-08-31 | Saranas, Inc. | $1,000 | Research payment | Cash or cash equivalent | SARANAS SAFE-MCS STUDY | 2022 | |
| 2022-08-31 | Saranas, Inc. | $100 | Research payment | Cash or cash equivalent | SARANAS SAFE-MCS STUDY | 2022 | |
| 2022-08-31 | Saranas, Inc. | $100 | Research payment | Cash or cash equivalent | SARANAS SAFE-MCS STUDY | 2022 | |
| 2022-08-25 | Abbott Laboratories | $500 | Research payment | Cash or cash equivalent | Device, Cardiac Rhythm Management | Safety and Effectiveness Trial for the Nanostim Leadless Pacemaker | 2022 |
| 2022-08-17 | Gilead Sciences, Inc. | $683 | Research payment | Cash or cash equivalent | A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhib | 2022 | |
| 2022-08-16 | PFIZER INC. | $61,617 | Research payment | Cash or cash equivalent | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI | 2022 | |
| 2022-08-12 | JAZZ PHARMACEUTICALS INC. | $83,250 | Research payment | Cash or cash equivalent | VYXEOS Drug, HEMATOLOGY/ONCOLOGY | A PHASE 3 RANDOMIZED TRIAL FOR PATIENTS WITH DE NOVO AML COMPARING STANDARD THERAPY INCLUDING GEMTUZUMAB OZOGAMICIN GO T | 2022 |
| 2022-08-03 | Genentech, Inc. | $5,000 | Research payment | Cash or cash equivalent | Xeloda Drug, BioOncology | MYTACTIC TARGETING ACTIONABLE MUTATION STUDY IN CANCER US PIIA MULTICENTER NONRANDOMIZED OPEN LBL | 2022 |
| 2022-08-03 | Abbott Laboratories | $3,330 | Research payment | Cash or cash equivalent | Device, Cardiac Rhythm Management | Safety and Effectiveness Trial for the Nanostim Leadless Pacemaker | 2022 |
| 2022-08-03 | Genentech, Inc. | $2,040 | Research payment | Cash or cash equivalent | Xeloda Drug, BioOncology | MYTACTIC TARGETING ACTIONABLE MUTATION STUDY IN CANCER US PIIA MULTICENTER NONRANDOMIZED OPEN LBL | 2022 |
| 2022-08-01 | Medtronic, Inc. | $2,897 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | TAVR Low Risk | 2022 |
| 2022-08-01 | Medtronic, Inc. | $2,897 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | TAVR Low Risk | 2022 |
| 2022-07-29 | PFIZER INC. | $40,365 | Research payment | Cash or cash equivalent | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI | 2022 | |
| 2022-07-27 | Celgene Corporation | $1,910 | Research payment | Cash or cash equivalent | Revlimid Drug, Hematology | Connect MDS/AML - Connect Myeloid: The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (A | 2022 |
| 2022-07-22 | Eli Lilly and Company | $16,750 | Research payment | Cash or cash equivalent | STUDY OF LOXO-305 VERSUS INVESTIGATOR'S CHOICE (IDELAR OR BR) IN PATIENTS WITH PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LE | 2022 | |
| 2022-07-20 | Genentech, Inc. | $3,167 | Research payment | Cash or cash equivalent | Xeloda Drug, BioOncology | MYTACTIC TARGETING ACTIONABLE MUTATION STUDY IN CANCER US PIIA MULTICENTER NONRANDOMIZED OPEN LBL | 2022 |
| 2022-07-20 | Genentech, Inc. | $1,947 | Research payment | Cash or cash equivalent | Xeloda Drug, BioOncology | MYTACTIC TARGETING ACTIONABLE MUTATION STUDY IN CANCER US PIIA MULTICENTER NONRANDOMIZED OPEN LBL | 2022 |
| 2022-07-20 | Genentech, Inc. | $1,947 | Research payment | Cash or cash equivalent | Xeloda Drug, BioOncology | MYTACTIC TARGETING ACTIONABLE MUTATION STUDY IN CANCER US PIIA MULTICENTER NONRANDOMIZED OPEN LBL | 2022 |
| 2022-07-20 | Gilead Sciences, Inc. | $1,259 | Research payment | Cash or cash equivalent | A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhib | 2022 | |
| 2022-07-20 | Genentech, Inc. | $62 | Research payment | Cash or cash equivalent | Xeloda Drug, BioOncology | MYTACTIC TARGETING ACTIONABLE MUTATION STUDY IN CANCER US PIIA MULTICENTER NONRANDOMIZED OPEN LBL | 2022 |
| 2022-07-18 | Gilead Sciences, Inc. | $30 | Research payment | Cash or cash equivalent | A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhib | 2022 | |
| 2022-07-15 | KARL STORZ Endoscopy-America | $61 | Long term medical supply or device loan | In-kind items and services | HOPKINS Device, CARDIO-VASCULAR SURGERY | 2022 | |
| 2022-07-15 | Penumbra, Inc. | $50 | Research payment | Cash or cash equivalent | Indigo System Device, Peripheral Intervention | STRIKE-PE | 2022 |
| 2022-07-12 | JAZZ PHARMACEUTICALS INC. | $135,375 | Research payment | Cash or cash equivalent | VYXEOS Drug, HEMATOLOGY/ONCOLOGY | A PHASE 3 RANDOMIZED TRIAL FOR PATIENTS WITH DE NOVO AML COMPARING STANDARD THERAPY INCLUDING GEMTUZUMAB OZOGAMICIN GO T | 2022 |
| 2022-07-12 | Medtronic, Inc. | $7,165 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | CoreValve SURTAVI | 2022 |
| 2022-07-12 | Medtronic, Inc. | $7,165 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | CoreValve SURTAVI | 2022 |
| 2022-07-08 | Saranas, Inc. | $1,173 | Research payment | Cash or cash equivalent | SARANAS SAFE-MCS STUDY | 2022 | |
| 2022-07-07 | Genetesis, Inc. | $20,370 | Research payment | Cash or cash equivalent | ACCMED | 2022 | |
| 2022-07-05 | Penumbra, Inc. | $2,000 | Research payment | Cash or cash equivalent | Indigo System Device, Peripheral Intervention | CHEETAH | 2022 |
| 2022-07-01 | PFIZER INC. | $196 | Research payment | Cash or cash equivalent | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI | 2022 | |
| 2022-06-30 | Genentech, Inc. | $1,500 | Research payment | Cash or cash equivalent | TNKase Biological, Metabolism & Primary Care | TENECTEPLASE IN STROKE PATIENTS BETWEEN 4 5 AND 24 HOURS | 2022 |
| 2022-06-29 | PFIZER INC. | $14,971 | Research payment | Cash or cash equivalent | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI | 2022 | |
| 2022-06-23 | Medtronic, Inc. | $4,262 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | SMART Trial | 2022 |
| 2022-06-23 | Medtronic, Inc. | $4,262 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | SMART Trial | 2022 |
| 2022-06-23 | Saranas, Inc. | $1,173 | Research payment | Cash or cash equivalent | SARANAS SAFE-MCS STUDY | 2022 | |
| 2022-06-22 | Genetesis, Inc. | $8,850 | Research payment | Cash or cash equivalent | ACCMED | 2022 | |
| 2022-06-22 | Saranas, Inc. | $2,558 | Research payment | Cash or cash equivalent | SARANAS SAFE-MCS STUDY | 2022 | |
| 2022-06-22 | Gilead Sciences, Inc. | $2,138 | Research payment | Cash or cash equivalent | A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhib | 2022 | |
| 2022-06-22 | Saranas, Inc. | $100 | Research payment | Cash or cash equivalent | SARANAS SAFE-MCS STUDY | 2022 | |
| 2022-06-16 | Penumbra, Inc. | $690 | Research payment | Cash or cash equivalent | Indigo System Device, Peripheral Intervention | STRIKE-PE | 2022 |
| 2022-06-15 | Genentech, Inc. | $15,857 | Research payment | Cash or cash equivalent | Xeloda Drug, BioOncology | MYTACTIC TARGETING ACTIONABLE MUTATION STUDY IN CANCER US PIIA MULTICENTER NONRANDOMIZED OPEN LBL | 2022 |
| 2022-06-15 | PFIZER INC. | $6,039 | Research payment | Cash or cash equivalent | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI | 2022 | |
| 2022-06-15 | Genentech, Inc. | $5,603 | Research payment | Cash or cash equivalent | Xeloda Drug, BioOncology | MYTACTIC TARGETING ACTIONABLE MUTATION STUDY IN CANCER US PIIA MULTICENTER NONRANDOMIZED OPEN LBL | 2022 |
| 2022-06-15 | Genentech, Inc. | $2,040 | Research payment | Cash or cash equivalent | Xeloda Drug, BioOncology | MYTACTIC TARGETING ACTIONABLE MUTATION STUDY IN CANCER US PIIA MULTICENTER NONRANDOMIZED OPEN LBL | 2022 |
| 2022-05-26 | Penumbra, Inc. | $3,131 | Research payment | Cash or cash equivalent | Indigo System Device, Peripheral Intervention | STRIKE-PE | 2022 |
| 2022-05-20 | Impulse Dynamics (USA) Inc. | $1,750 | Research payment | Cash or cash equivalent | OPTIMIZER Device, Cardiovascular Device | Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy | 2022 |
| 2022-05-18 | Gilead Sciences, Inc. | $963 | Research payment | Cash or cash equivalent | A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhib | 2022 | |
| 2022-05-11 | Gilead Sciences, Inc. | $7,680 | Research payment | Cash or cash equivalent | A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhib | 2022 | |
| 2022-05-10 | Medtronic, Inc. | $800 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | SMART Trial | 2022 |
| 2022-05-10 | Medtronic, Inc. | $800 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | SMART Trial | 2022 |
| 2022-05-05 | Penumbra, Inc. | $1,750 | Research payment | Cash or cash equivalent | Indigo System Device, Peripheral Intervention | STRIKE-PE | 2022 |
| 2022-05-05 | Abbott Laboratories | $500 | Research payment | Cash or cash equivalent | Device, Cardiac Rhythm Management | Safety and Effectiveness Trial for the Nanostim Leadless Pacemaker | 2022 |
| 2022-05-05 | Penumbra, Inc. | $250 | Research payment | Cash or cash equivalent | Indigo System Device, Peripheral Intervention | STRIKE-PE | 2022 |
| 2022-05-04 | E.R. Squibb & Sons, L.L.C. | $14,450 | Research payment | Cash or cash equivalent | A Global, Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of BMS-986177, an Oral Factor XIa In | 2022 | |
| 2022-04-27 | Abbott Laboratories | $3,340 | Research payment | Cash or cash equivalent | Device, Cardiac Rhythm Management | Safety and Effectiveness Trial for the Nanostim Leadless Pacemaker | 2022 |
| 2022-04-26 | Saranas, Inc. | $9,532 | Research payment | Cash or cash equivalent | SARANAS SAFE-MCS STUDY | 2022 | |
| 2022-04-26 | Saranas, Inc. | $5,316 | Research payment | Cash or cash equivalent | SARANAS SAFE-MCS STUDY | 2022 | |
| 2022-04-21 | Octapharma USA, Inc. | $1,200 | Research payment | Cash or cash equivalent | PANZYGA Biological, IMMUNOLOGY | NGAM-12 | 2022 |
| 2022-04-14 | Penumbra, Inc. | $13,053 | Research payment | Cash or cash equivalent | Indigo System Device, Peripheral Intervention | STRIKE-PE | 2022 |
| 2022-04-14 | PFIZER INC. | $1,067 | Research payment | Cash or cash equivalent | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI | 2022 | |
| 2022-04-14 | Abbott Laboratories | $1,000 | Research payment | Cash or cash equivalent | Device, Cardiac Rhythm Management | Safety and Effectiveness Trial for the Nanostim Leadless Pacemaker | 2022 |
| 2022-04-14 | Medtronic, Inc. | $180 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | CoreValve SURTAVI | 2022 |
| 2022-04-14 | Medtronic, Inc. | $180 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | CoreValve SURTAVI | 2022 |
| 2022-03-24 | Medtronic, Inc. | $1,478 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | SMART Trial | 2022 |
| 2022-03-24 | Medtronic, Inc. | $1,478 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | SMART Trial | 2022 |
| 2022-03-23 | Gilead Sciences, Inc. | $1,238 | Research payment | Cash or cash equivalent | A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhib | 2022 | |
| 2022-03-23 | Penumbra, Inc. | $828 | Research payment | Cash or cash equivalent | Indigo System Device, Peripheral Intervention | STRIKE | 2022 |
| 2022-03-23 | Penumbra, Inc. | $696 | Research payment | Cash or cash equivalent | Indigo System Device, Peripheral Intervention | STRIKE | 2022 |
| 2022-03-23 | Penumbra, Inc. | $552 | Research payment | Cash or cash equivalent | Indigo System Device, Peripheral Intervention | STRIKE | 2022 |
| 2022-03-23 | Penumbra, Inc. | $483 | Research payment | Cash or cash equivalent | Indigo System Device, Peripheral Intervention | STRIKE | 2022 |
| 2022-03-23 | Penumbra, Inc. | $395 | Research payment | Cash or cash equivalent | Indigo System Device, Peripheral Intervention | STRIKE | 2022 |
| 2022-03-23 | Penumbra, Inc. | $103 | Research payment | Cash or cash equivalent | Indigo System Device, Peripheral Intervention | STRIKE | 2022 |
| 2022-03-23 | Penumbra, Inc. | $96 | Research payment | Cash or cash equivalent | Indigo System Device, Peripheral Intervention | STRIKE | 2022 |
| 2022-03-23 | Penumbra, Inc. | $48 | Research payment | Cash or cash equivalent | Indigo System Device, Peripheral Intervention | STRIKE | 2022 |
| 2022-03-16 | PFIZER INC. | $8,963 | Research payment | Cash or cash equivalent | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI | 2022 | |
| 2022-03-15 | AngioDynamics, Inc. | $12,333 | Long term medical supply or device loan | In-kind items and services | NanoKnife Device, Oncology Surgery | 2022 | |
| 2022-03-14 | Genetesis, Inc. | $15,090 | Research payment | Cash or cash equivalent | ACCMED | 2022 | |
| 2022-03-13 | Genetesis, Inc. | $16,910 | Research payment | Cash or cash equivalent | ACCMED | 2022 | |
| 2022-03-11 | Abbott Laboratories | $2,000 | Research payment | Cash or cash equivalent | THORATEC HEARTMATE 3 LVAS IMPLANT KIT Device, Heart Failure | Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow Percutaneous Left Ventricular Support Device (SHIELD II) | 2022 |
| 2022-03-04 | Genentech, Inc. | $5,000 | Research payment | Cash or cash equivalent | Xeloda Drug, BioOncology | MYTACTIC TARGETING ACTIONABLE MUTATION STUDY IN CANCER US PIIA MULTICENTER NONRANDOMIZED OPEN LBL | 2022 |
| 2022-03-04 | Genentech, Inc. | $2,842 | Research payment | Cash or cash equivalent | Xeloda Drug, BioOncology | MYTACTIC TARGETING ACTIONABLE MUTATION STUDY IN CANCER US PIIA MULTICENTER NONRANDOMIZED OPEN LBL | 2022 |
| 2022-03-04 | Genentech, Inc. | $1,500 | Research payment | Cash or cash equivalent | Xeloda Drug, BioOncology | MYTACTIC TARGETING ACTIONABLE MUTATION STUDY IN CANCER US PIIA MULTICENTER NONRANDOMIZED OPEN LBL | 2022 |
| 2022-02-25 | PFIZER INC. | $97,969 | Research payment | Cash or cash equivalent | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI | 2022 | |
| 2022-02-24 | Alexion Pharmaceuticals, Inc. | $2,895 | Research payment | Cash or cash equivalent | KANUMA Biological, Rare Disease | An Observational Disease and Clinical Outcomes Registry of Patients with Lysosomal Acid Lipase (LAL) Deficiency | 2022 |
| 2022-02-09 | Abbott Laboratories | $6,010 | Research payment | Cash or cash equivalent | Device, Cardiac Rhythm Management | Safety and Effectiveness Trial for the Nanostim Leadless Pacemaker | 2022 |
| 2022-02-07 | Genetesis, Inc. | $21,510 | Research payment | Cash or cash equivalent | ACCMED | 2022 | |
| 2022-02-04 | PFIZER INC. | $145,723 | Research payment | Cash or cash equivalent | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI | 2022 | |
| 2022-02-04 | Philips North America LLC | $4,000 | Research payment | Cash or cash equivalent | (V021) iFR Device, Medical Device | ReVEAL iFR | 2022 |
| 2022-02-04 | Philips North America LLC | $2,400 | Research payment | Cash or cash equivalent | (V021) iFR Device, Medical Device | ReVEAL iFR | 2022 |
| 2022-02-04 | Philips North America LLC | $1,050 | Research payment | Cash or cash equivalent | (V021) iFR Device, Medical Device | ReVEAL iFR | 2022 |
| 2022-02-04 | Abbott Laboratories | $500 | Research payment | Cash or cash equivalent | Device, Cardiac Rhythm Management | Safety and Effectiveness Trial for the Nanostim Leadless Pacemaker | 2022 |
| 2022-02-03 | Medtronic, Inc. | $5,000 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | SMART Trial | 2022 |
| 2022-02-03 | Medtronic, Inc. | $5,000 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | SMART Trial | 2022 |
| 2022-02-02 | Medtronic, Inc. | $4,121 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | TAVR Low Risk | 2022 |
| 2022-02-02 | Medtronic, Inc. | $4,121 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | TAVR Low Risk | 2022 |
| 2022-02-02 | Medtronic, Inc. | $300 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | Optimize Pro | 2022 |
| 2022-02-02 | Medtronic, Inc. | $300 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | Optimize Pro | 2022 |
| 2022-01-19 | Saranas, Inc. | $100 | Research payment | Cash or cash equivalent | SARANAS SAFE-MCS STUDY | 2022 | |
| 2022-01-18 | Medtronic, Inc. | $9,441 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | CoreValve SURTAVI | 2022 |
| 2022-01-18 | Medtronic, Inc. | $9,441 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | CoreValve SURTAVI | 2022 |
| 2022-01-16 | Saranas, Inc. | $50 | Research payment | Cash or cash equivalent | SARANAS SAFE-MCS STUDY | 2022 | |
| 2022-01-11 | Abbott Laboratories | $415 | Research payment | Cash or cash equivalent | ABSORB GT1 Device, Vascular | A Clinical Evaluation of Absorb BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects | 2022 |
| 2022-01-08 | PFIZER INC. | $31,324 | Research payment | Cash or cash equivalent | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI | 2022 | |
| 2022-01-06 | Saranas, Inc. | $8,000 | Research payment | Cash or cash equivalent | SARANAS SAFE-MCS STUDY | 2022 | |
| 2022-01-05 | Cochlear Americas | $165 | Debt forgiveness | Cash or cash equivalent | Cochlear Device, Implantable hearing solution | 2022 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Detroit, MI, county Wayne County, MI, state Michigan; placed by its city name.
| Measure | Place (city or town) Detroit, MI | County Wayne County, MI | State Michigan |
|---|---|---|---|
| Population B01003 | 638,530 | 1,772,259 | 10,077,761 |
| Population, 2020 census P1 | 639,111 | 1,793,561 | 10,077,331 |
| Median age B01002 | 35.2 | 37.9 | 40.2 |
| Under 18 B01001 | 24.8% | 23.6% | 21.2% |
| 65 and over B01001 | 15.1% | 16.6% | 18.6% |
| Households B11001 | 257,998 | 700,591 | 4,076,369 |
| Foreign born B05002 | 6.6% | 10.3% | 7.2% |
| Median household income B19013 | $39,938 | $60,539 | $72,875 |
| Median family income B19113 | $49,398 | $79,522 | $93,357 |
| Per capita income B19301 | $24,594 | $34,906 | $40,735 |
| Poverty rate B17001 | 32.7% | 20.8% | 13.2% |
| Unemployment rate B23025 | 14.0% | 8.7% | 5.7% |
| Civilian labor force B23025 | 268,955 | 828,838 | 5,018,449 |
| Mean commute (minutes) B08013 | 24.8 | 24.7 | 24.2 |
| Bachelor's degree or higher B15003 | 18.1% | 27.6% | 32.4% |
| Housing units B25001 | 329,393 | 801,083 | 4,622,236 |
| Owner-occupied B25003 | 50.3% | 64.8% | 73.2% |
| Renters B25003 | 49.7% | 35.2% | 26.8% |
| Median home value B25077 | $83,900 | $178,500 | $231,600 |
| Median gross rent B25064 | $1,074 | $1,132 | $1,129 |
| White, not Hispanic B03002 | 10.8% | 47.9% | 72.4% |
| Black B03002 | 75.0% | 36.6% | 13.1% |
| Hispanic or Latino B03002 | 8.3% | 6.9% | 5.9% |
| Asian B03002 | 1.7% | 3.7% | 3.4% |
| American Indian and Alaska Native B03002 | 0.2% | 0.2% | 0.3% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Detroit, MI.
Comments